“All registration procedures have been completed. The vaccine will soon be available on the commercial market. High demand for this vaccine is expected, based on feedback from livestock farms. It is a unique product in the Russian market, with no similar domestic alternatives currently available,” Ilya Chvala told V&L.
He also mentioned that the vaccine is specifically designed to prevent infectious mastitis and that the institution’s professionals spent several years studying livestock and dairy farms in order to develop it.
In search of vaccine strains, scientists collected over 400 samples of biomaterial from cows, and pathogens were isolated in 75% of them.
The immunobiological’s antigenic composition includes inactivated bacterial cells of Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus uberis, two strains of Staphylococcus aureus, Staphylococcus hyicus, and two strains of Escherichia coli.
Besides that, seven more vaccines developed by the FGBI ARRIAH have been authorized in 2023:
- the ‘Carnican-4’ vaccine against canine distemper, canine enteric parvovirus and coronavirus, and canine adenovirus in dogs;
- the ‘ARRIAH-Bimivak’ vaccine against avian mycoplasmosis and infectious synovitis in poultry;
- the inactivated emulsion vaccine against infectious bursal disease and viral tenosynovitis in poultry (‘ARRIAH-IBD+ARV’);
- the live dry vaccine against Newcastle disease, based on the ‘ARRIAH NB-En’ strain;
- the ‘Carnifel-PCH’ vaccine, effective against feline panleukopenia, feline calicivirus, and feline viral rhinotracheitis
- the inactivated emulsion vaccine against Newcastle disease, infectious bronchitis in chickens (multi-strain), infectious bursal disease, and metapneumovirus infection in birds (‘ARRIAH-ND+IBC+IBD+aMPV’);
- the ‘Carnican-5’ vaccine against canine distemper, canine enteric parvovirus and coronavirus, canine adenovirus, and rabies in dogs.
